Elsubrutinib,Upadacitinib,ABBV-599
AbbVie
['elsubrutinib', 'upadacitinib', 'sleek', 'abbvie']
exciting new data in sle from eular! results from abbvie s phase ii sleek trial show upadacitinib alone, or in combination with elsubrutinib achieved the primary endpoint of 4 point reduction in sri-4 at week 24, maintained to week 48 with no new safety signals.
A free educational resource for anyone involved in lupus research and treatment. Guided by a global steering committee chaired by @EdVital.